Polycystic ovary syndrome

Journal of Endocrinology, Metabolism and Diabetes of South Africa

Volumn 14, Issue 2, 2009, Pages 86-94

  Maharaj, Sureka ^a   Amod, A ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

PCOD; PCOM; PCOS; Polycystic ovarian disease; Polycystic ovarian morphology; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIANDROGEN; CLOMIFENE; COSMETIC; CYPROTERONE ACETATE; DIANE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; INSULIN SENSITIZING AGENT; METFORMIN; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACNE; ADJUVANT THERAPY; ALOPECIA; ANOVULATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE INFERTILITY; FLUID RETENTION; FRACTURE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERGONADOTROPIC HYPOGONADISM; HYPERPROLACTINAEMIC ANOVULATION; HYPERPROLACTINEMIA; HYPOGONADOTROPHIC HYPOGONADAL ANOVULATION; INSULIN RESISTANCE; LIBIDO; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMOGONADOTROPHIC NORMOOESTROGENIC ANOVULATION; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PSEUDOHERMAPHRODITISM; RECEPTOR BLOCKING; REVIEW; RISK FACTOR; SIDE EFFECT; THYROID DISEASE; WEIGHT GAIN;

EID: 78649700825     PISSN: 16089677     EISSN: None     Source Type: Journal    
DOI: 10.1080/22201009.2009.10872199     Document Type: Review

References (119)

1. Vallisneri A. Istoria della Generazione dell'Uomo, e degli Animali, se sia da' vermicelli spermatici, o dalle uova. Venezia: Appreso Gio Gabbriel Hertz, 1721.
2. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.
3. Yen SSC, Vela P, Rankin J. 1970 Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab. 30:435-442
4. Raj SG, Thompson IE, Berger MJ, Talert LM and Taymor ML. Diagnostic value of androgen measurements in polycystic ovary syndrome. Obstet Gynecol. 1978; 52:169-171
5. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet. 1988;1:870-2.
6. Abdel Gadir A, Khatim MS, Mowafi RA, Alnaser HM, Muharib NS, Shaw RW. Implications of ultrasonically diagnosed polycystic ovaries (1)-Correlation with basal hormonal profiles. Human Reproduction. 1992;7:453-7
7. Burghen GA, Givens JR, Kitabchi AE. 1980 Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113-116
8. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
9. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab.1998;83:3078-3082. (Pubitemid 28500937)
10. Goodarzi MO, Quinones MJ, Azziz Rl. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 2005;84:766-9.
11. Holte J, Gennarelli G, Wide Ll. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143-50.
12. Ibanez L, Dimartino-Nardi J, Potau N. Premature adrenarche - normal variant or forerunner of adult disease? Endocr Rev 2000;21:671-96.
13. Kahsar-Miller M, Nixon C, Boots LR, et al. Prevalence of the polycystic ovary syndrome (PCOS) among first degree relatives of patients with PCOS. Fertil Steril 2001;75:53-8.
14. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women Experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453-62. (Pubitemid 38269843)
15. Carmina E, Rosato F, Janni A. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91(1):2-6.
16. Perkins RB, Hall JE, Martin KA. Neuroendocrine abnormalities in hypothalamic amenorrhoea: spectrum, stability, and response to neurotransmitter modulation. J Clin Endocrinol Metab 1999;84:1905-1911.
17. Futterweit W, Yeh HC, Mechanick JI. Ultrasonographic study of ovaries of 19 women with weight loss-related hypothalamic oligo-amenorrhoea. Biomed Pharmacother 1988;42:279-83.
18. Jeff G. Wang and Rogerio A. Lobo The complex relationship between hypothalamic amenorrhoea and Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2008;Vol. 93, No. 4 1394-1397.
19. Laml T, Schulz-Lobmeyr I, Obruca A, Huber JC and Hartmann BW.Premature ovarian failure: etiology and prospects. 2000. Gynecol Endocrinol 14, 292-302.
20. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific, 1992:377-84.
21. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J. Clin. Endocrinol. Metab, 2006;91:4237-4245.
22. Barth JH, Yasmin E and Balen AH. The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clinical Endocrinology (2007) 67, 811-815. (Pubitemid 350135121)
23. Azziz, R. Controversy in clinical endocrinology. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. Journal of Clinical Endocrinology and Metabolism. 2006;91,781-785.
24. Franks et al controversy in clinical endocrine: diagnosis of PCOS: in defence of the Rotterdam criteria : J Clin Endocrinol Metab 91:786-789.
25. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries-a common finding in normal women. Lancet. 1988;16;1(8590):870-2.
26. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol. 1994;34(1):67-72.
27. Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab. 2005;90(5):2571-9. (Pubitemid 40686293)
28. Chang W, Knochenhauer ES, Bartolucci AA, et al. Phenotypic spectrum of the polycystic ovary syndrome (PCOS): Clinical and biochemical characterization of the major clinical subgroups. Fertil Steril 2005;83:1717-23.
29. Barber TM; Wass JAH, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clinical Endocrinology. 2007;66(4):513-517.
30. Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: Insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2004;89:4343-4350.
31. Apridonidze T, Essah PA, Luorno MJ. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005,90:1929-1935. (Pubitemid 40586223)
32. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113:1210-1217.
33. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report Fertility and Sterility. 2009;91(2):456-488.
34. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med 2001;111:602-6.
35. Eden JA, Place J, Carter GD, et al. Is the polycystic ovary a cause of infertility in the ovulatory woman? Clin Endocrinol (Oxf) 1989;30:77-82.
36. Kousta E, White DM, Cela E, et al. The prevalence of polycystic ovaries in women with infertility. Hum Reprod 1999;14:2720-3.
37. Carmina E, Chu MC, Longo RA, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-9.
38. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370(9588):685-695.
39. Ferriman D and J.D. Gallwey JD. Clinical assessment of body hair growth in women, J Clin Endocrinol Metab. 1961;21:1440-1447.
40. DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab 2006;91:1345-50.
41. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002;57:343-50.
42. Rosenfield RL. Pilosebaceous physiology in relation to hirsutism and acne. Clin Endocrinol Metab 1986;15:341-362.
43. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol. 1997;24:223-9.
44. Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 2003;149:439-42. (Pubitemid 37461526)
45. Futterweit W, Dunaif A, Yeh HC, et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988;19:831-6.
46. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter D and Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod. 2003;18:598-603.
47. Balen AH, Lave JSE, Tan S. Ultrasound assessment of the polycystic ovary: International consensus definitions. Hum Reprod Update 2003;9:505-514.
48. Adams J, Polson D.W. and Franks, S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. Clin. Res. Ed. 1986;293,355-359.
49. Farquhar, C.M., Birdsall, M., Manning, P., Mitchell, J.M. and France, J.T. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust. N Z J. Obstet. Gynaecol. 1994;34,67-72.
50. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A: A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001;76(2):326-331. (Pubitemid 32703821)
51. van der Westhuizen S; van der Spuy ZM. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome. Ultrasound Obstet Gynecol. 1996;7(5):335-41.
52. Nardo, L.G., Buckett, W.M. and Khullar, V. Determination of the best-fitting ultrasound formulaic method for ovarian volume measurement in women with polycystic ovary syndrome. Fertil. Steril.2003;79,632-633.
53. Polson DW, Adams J, Wadsworth J. Polycystic ovaries: a common finding in normal women. Lancet 1988;1:870-2. (Pubitemid 18092411)
54. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, Lobo RA Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod. 1997;12:905-909. (Pubitemid 27271742)
55. Merrill JA The morphology of the prepubertal ovary: relationship to the polycystic ovary syndrome. South Med J. 1963;56:225-231.
56. Plate WP. Ovarian changes after long-term oral contraception. Acta Endocrinol Copenh. 1967 May;55(1):71-77.
57. Franks, S, Adams J, Mason HD and Polson DW .Ovulatory disorders in women with polycystic ovary syndrome. Clin. Obstet. Gynecol. 1985;12,605-632.
58. Quan A, Charles D, Craig JM. Histologic and functional consequences of periovarian adhesions. Obstet Gynecol 1963;22:96-101.
59. Burrell LM, Murdoch A, Angus B, White MC Autoimmune ovarian failure with elevated serum levels of luteinizing hormone and enlarged ovaries. Case report. Br J Obstet Gynaecol.1990;97:362-364. (Pubitemid 20153692)
60. Biscotti CV, Hart WR, Lucas JG. Cystic ovarian enlargement resulting from autoimmune oophoritis. Obstet Gynecol. 1989;74:492-495.
61. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
62. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:162-8.
63. Laitinen J, Taponen S, Martikainen H, Pouta A, Millwood I, Hartikainen AL, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710-5. (Pubitemid 36712955)
64. Dunaif A. Insulin resistance and the polycystic ovarian syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
65. Holte J, Bergh T, Berne Ch, Berglund L and Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994 .78,1052-1058.
66. Ehrmann DA, Sturis J, Byrne MM, Karrison T and Rosenfeld RL Insulin secretory defects in polycystic ovary syndrome. J Clin Invest 1995;96,520-527.
67. Legro RS. A 27-Year-Old Woman with a Diagnosis of Polycystic Ovary Syndrome. JAMA. 2007;297(5):509-519. (Pubitemid 46220806)
68. Legro RS, Kunselman AR, Dodson WC and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-169.
69. Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994;61:455-60.
70. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998;69:236-41. (Pubitemid 28117100)
71. Hamburg R. Pregnancy complications in PCOS. Best Practice & Research Clinical Endocrinology & Metabolism. 2006; Vol. 20, No. 2:281-292.
72. Colton SA, Pieper GM, Downs SM. Altered meiotic regulation in oocytes of diabetic mice. Biolog Reprod. 2002; 67:220-231.
73. Jakubowicz D, Iuorno M, Roberts K, Nestler J. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. JCEM. 2002.87:524-529. (Pubitemid 34158214)
74. Regan L, Owen EJ & Jacobs HS. Hypersecretion of luteinising hormone, infertility and miscarriage. Lancet. 1990;336:1141-1144.
75. Glueck CJ,Wang P, Fontaine RN et al. Plasmonogen inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589-1595.
76. Wang JX, Davies MJ & Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Human Reproduction. 2001;16:2606-2609.
77. Adam H. Balen, Seang-Lin Tan, Jane MacDougall and Howard S. Jacobs. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction, Vol. 8, No. 6, pp. 959-964, 1993.
78. L. Engmann, N. Maconochie, P. Sladkevicius, J. Bekir, S. Campbell, and S. L. Tan The outcome of invitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology Hum. Reprod. January 1, 1999;14(1):167-171.
79. Wang JX, Davies MJ, Norman RJ. Obesity increases the risk of spontaneous abortion during infertility treatment. Obes Res. 2002;10:551-554.
80. Schieve LA, Tatham L, Peterson HB, Toner J, Jeng G. Spontaneous abortion among pregnancies conceived using assisted reproductive technology in the United States. Obstet Gynecol. 2003;101(5 Pt 1):959-967. (Pubitemid 36561262)
81. Radon, P.A., McMahon, M.J. and Meyer, W.R. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet. Gynecol. 1999;94:194-197.
82. de Vries, M.J., Dekker, G.A. and Schoemaker, J. Higher risk of pre-eclampsia in the polycystic ovary syndrome. A case control study. Eur. J. Obstet. Gynecol. Reprod. Biol.1998;76:91-95.
83. Radon PA, McMahon MJ & Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstetrics and Gynecology.1999;94:194-197.
84. Kashyap S & Claman P. Polycystic ovary disease and the risk of pregnancy-induced hypertension. The Journal of Reproductive Medicine 2000;45:991-994. (Pubitemid 32016799)
85. Mikola M, Hiilesman V, Halttunen M. Obstetric outcome in women with polycystic ovary syndrome. Human Reproduction. 2001;16:226-229.
86. Haakova L, Cibula D, Rezabek K et al. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Human Reproduction. 2003;18:1438-1441.
87. Holte J, Gennarelli G, Wide L et al. High prevalence of polycystic ovaries and associated clinical, endocrine and metabolic features in women with previous gestational diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 1998;83:1143-1150. (Pubitemid 28496382)
88. Anttila L, Karjala K, Pentilla RA et al. Polycystic ovaries in women with gestational diabetes. Obstetrics and Gynecology 1998;92:13-16.
89. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2. [Erratum, Lancet 2003; 362:1082.].
90. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001;7:522-5.
91. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1175-80 (Pubitemid 32323001)
92. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 2004;18:685-706
93. Hall JE, Taylor AE, Hayes FJ, et al. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. J Endocrinol Invest 1998;21:602-11
94. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, indepentent of obesity, in polycystic ovary syndrome. Diabetes 1989);38:1165-1174
95. P.E. Hughesden, Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called hyperthecosis. Obstet Gynecol Survey 37 (1982), pp. 59-77
96. Wilson CM, McPhaul MJ 1996 A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 120:51-7
97. Horie K, Takakura K, Fujiwara H, Suginami H, Liao S, Mori. T: Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Human Reprod. 1992;7:184-190
98. Eppig JJ, Chesnel F, Hirao Y, O'Brien MJ, Pendola FL, Watanabe S, Wigglesworth K. Oocyte control of granulosa cell development: how and why. Biol Reprod.1997 12:127-132. (Pubitemid 27528791)
99. Legro, R.S. The genetics of polycystic ovary syndrome. 1995. Am. J. Med. 98, suppl 1A, 9S-16S.
100. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006 Aug;30(1):19-26. (Pubitemid 46020326)
101. Abbott DH, Dumesic DA, Eisner JR, Colman RJ & Kemnitz JW Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends in Endocrinology and Metabolism.1998;9:62-67.
102. Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovarian syndrome. Hum Reprod 2006;2:80-89.
103. J Vrbikova and D Cibula, Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005;11:277-291. (Pubitemid 40668112)
104. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK and Tapanainen JS Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. 2000. J Clin Endocrinol Metab 85, 3161-3168.
105. Prelevic GM, Wurzburger MI, Trpkovic D and Balint-Peric L Effects of a low-dose estrogenantiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol.1990;4:157-168. (Pubitemid 20333183)
106. Farquhar C, Lee O, Toomath R, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Sys Rev. 2003; 2003(4);CD000194.
107. Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril. 2005;84(6):1693-1697.
108. Karakurt F, Sahin I, Güler S, Demirbas B, Culha C, Serter R, Aral Y, Bavbek N. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyl oestradiol/cyproterone acetate in the treatment of hirsutism: a randomized controlled study. Adv Ther. 2008; Apr 25(4):321-8.
109. Swiglo BA, Cosma M, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Erwin PJ Montori. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008 Apr;93(4):1153-60. (Pubitemid 351519699)
110. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000; 85(1):89-94. (Pubitemid 32268796)
111. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007 ;( 1):CD005552.
112. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and Metaanalysis of randomized controlled trials. JClin Endocrinol Metab. 2008 Apr;93(4):1135-42.
113. Olympia Koulouri and Gerard S. Conway. A systematic review of commonly used medical treatments for hirsutism in women. Clinical Endocrinology (2008) 68:800-805.
114. Palomba et al. Metformin in the PCOS: a comprehensive review. Endocrine Reviews 2009; Feb; Vol 30(1):p1-51.
115. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-74.
116. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951-953.
117. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Human Reproduction 2004;19:2474-83. (Pubitemid 39481270)
118. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction 2008. Vol.23;No.3: pp. 462-477.
119. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome. Hum Reprod Update. 2008;14:193-8.